# EIF4EBP1

Source: https://onco.cc/targets/eif4ebp1/  
OnCo record `eif4ebp1` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

EIF4EBP1 (Eukaryotic translation initiation factor 4E-binding protein 1) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer and Gastric & gastro-oesophageal junction cancer.

## Summary

Repressor of translation initiation that regulates EIF4E activity by preventing its assembly into the eIF4F complex: hypophosphorylated form competes with EIF4G1/EIF4G3 and strongly binds to EIF4E, leading to repress translation. In contrast, hyperphosphorylated form dissociates from EIF4E, allowing interaction between EIF4G1/EIF4G3 and EIF4E, leading to initiation of translation. Mediates the regulation of protein translation by hormones, growth factors and other stimuli that signal through the MAP kinase and mTORC1 pathways.

CIViC holds 2 clinical evidence items and 0 assertions across 1 variant, naming Everolimus, MTOR Kinase Inhibitor PP242, WYE354 and Dactolisib.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: eukaryotic translation initiation factor 4E binding protein 1; Eukaryotic translation initiation factor 4E-binding protein 1; PHAS-I; 4E-BP1
- Tags: cancer-genes-wave
- Symbol: EIF4EBP1
- Class: other
- Biology: Repressor of translation initiation that regulates EIF4E activity by preventing its assembly into the eIF4F complex: hypophosphorylated form competes with EIF4G1/EIF4G3 and strongly binds to EIF4E, leading to repress translation. In contrast, hyperphosphorylated form dissociates from EIF4E, allowing interaction between EIF4G1/EIF4G3 and EIF4E, leading to initiation of translation. Mediates the regulation of protein translation by hormones, growth factors and other stimuli that signal through the MAP kinase and mTORC1 pathways. Location: Cytoplasm; Nucleus (UniProt). Locus 8p11.23 (HGNC).
- Where found: Colorectal cancer: CIViC evidence names this disease; Gastric & gastro-oesophageal junction cancer: CIViC evidence names this disease

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 4 therapies; CIViC holds 2 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:3288: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3288
- UniProt Q13541: https://www.uniprot.org/uniprotkb/Q13541/entry
- NCBI Gene 1978: https://www.ncbi.nlm.nih.gov/gene/1978
- Ensembl ENSG00000187840: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000187840

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/)
- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/)

---
JSON: https://onco.cc/api/v1/entities/eif4ebp1.json